CompletedPhase 2NCT02362464

Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139

Studying Dendritic cell tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Hoyoung M Maeng, M.D.
National Cancer Institute (NCI)
Intervention
Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine(biological)
Enrollment
14 target
Eligibility
18 years · MALE
Timeline
20152022

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02362464 on ClinicalTrials.gov

Other trials for Dendritic cell tumor

Additional recruiting or active studies for the same condition.

See all trials for Dendritic cell tumor

← Back to all trials